FDMT · 4D Molecular Therapeutics Inc
United States · RS rating 83 · As of 2026-10-14
| Price | 12.20 USD |
|---|---|
| 1-day change | -1.3% |
| RS rating (overall / 1M / 3M / 12M) | 83 / 22 / 87 / 80 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 33 / 41 / 23 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -3.0% |
| Sales growth Q/Q | +94444.4% |
| Distance from 52-week high | +27.2% |
| Market cap (USD) | $490.6M |